http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Nazym Nigmatullina ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Aigerim Kalzhan ),( Nazym Nigmatullina ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: The role of mTOR inhibitors, such as EVL, has not been established for pediatric liver transplant recipients up to now, although data from adult solid organ graft transplantation are very promising. Major complications following pediatric liver transplantation in the long-term course include chronic graft rejection and CNI-derived nephrotoxicity. Methods: The purpose of our study was to report first results using EVL as a rescue therapy in pediatric liver transplant recipients for the following indications: chronic graft dysfunction n=12, suspected CNI toxicity n=3, hepatoblastoma n=2, and recurrence of primary sclerosing cholangitis post-Ltx n=1. Results: Four patients with chronic graft dysfunction developed completely normal liver function tests using EVL, six patients showed partial improvement, and two patients did not respond at all. One patient with CNI-induced nephropathy showed a slightly improved GFR. Both patients with hepatoblastoma did not develop any metastasis post-Ltx. First experience with EVL in pediatric liver transplant recipients shows promising results in patients with chronic graft failure when standard immunosuppression has failed. Conclusions: The future role of EVL in immunosuppressive protocols for children post-Ltx has to be proven by controlled clinical trials.
-
( Marina Khvan ),( Nazym Nigmatullina ),( Saltanat Rakhimzhanova ),( Samat Issakov ),( Venera Altynova ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Introduction: Hepatitis C virus (HCV) infection is an important co-morbidity in patients after kidney transplantation (KT) affecting patient and graft survival. In the era of Direct Acting Antiviral (DAA) drugs the current standards of management strongly suggest to treat HCV positive patient with end-stage renal disease (ESRD) before KT. However, in the conditions where this treatment is not available, KT remains the only lifesaving option for children with ESRD who is not able to sustain on dialysis any longer. Aim: Currently, there is limited data available about outcomes of pediatric patients with HCV after kidney transplantation. We studied the prevalence, clinical profile and outcome of HCV infection in KT pediatric recipients (KTPR) in Kazakhstan for the first time after the launching the National Pediatric KT Program in 2012. Methods: We studied pediatric patients who underwent KT from January 2012 to December 2018 at the Department of Nephrology, Dialysis and Transplantation, National Research Center of Mother and Child Health, University Medical Center, Nur-Sultan. HCV infection was defined as a positive anti-HCV antibody and/or HCV RNA PCR positivity. Control group included KTPRs with no evidence of HCV or hepatitis B virus (HBV) infection. Results: A total of 73 KTPRs were included. The mean age was 10.6 ± 4.5 years, male:female ratio was 1:1 and mean duration of post-transplant follow-up was 32 months. 9 patients (12%) had evidence of HCV infection. All HCV-positive patients underwent KT before DAAs were available in the country. Among them 4 patients were treated with interferon before KT, 4 patients had HCV infection by the time of KT and 1 patient developed de-novo HCV infection after KT. Although there was no statistical significant difference in patient survival (logrank P=0.82) and graft survival (log-rank P=0.416) between HCV-positive group and controls, the only death in HCV group was registered in the patient who had de-novo HCV infection after KT. 2 patients who were treated from HCV infection before KT lost their kidney grafts and returned on dialysis. Among 4 patients with persistent HCV infection by the time of KT, 2 were successfully treated with DAAs 5 years after KT without any side effects or worsening of graft function. 2 KTPRs still have chronic HCV infection Stage 0 - 1 with low viral load, normal liver function tests and normal kidney graft function over the 6 years after KT. Conclusions: In our cohort HCV-positive KTPRs did not have any difference in patient and graft survival comparing to KTPRs without HCV infection. The worst outcome had patient with de-novo developed HCV infection after KT. HCV treatment with DAA after KT was successful without deterioration of kidney graft function. Limitation: low number of HCV-positive KTPRs.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
